COGS per gram is calculated by dividing total manufacturing costs by total purified product output. Total costs include raw materials (media, buffers, resins), labor, facility depreciation, utilities, quality control, and waste disposal. For a typical monoclonal antibody process, sum your upstream costs (cell culture media, feeds, bioreactor operation) and downstream costs (chromatography resins, filtration membranes, buffer preparation), then divide by the number of grams of purified drug substance produced per batch. Our calculator automates this by letting you input your process parameters and generating a full cost breakdown across all manufacturing stages.

The largest cost drivers are typically facility-related (depreciation, maintenance) and downstream processing, not raw materials. For mammalian cell culture products, facility and capital costs can account for 40-60% of COGS, while downstream processing (chromatography resins, ultrafiltration membranes) contributes 20-30%. Media and raw materials typically represent 10-20%. Labor costs vary significantly by geography. At small scales (<2,000 L), fixed costs dominate, making per-gram costs very high. At commercial scale (10,000-25,000 L), improved volumetric productivity and economies of scale dramatically reduce per-gram costs. Single-use technologies have shifted some capital costs to consumables, reducing upfront investment but increasing variable costs.

Fed-batch is generally the most cost-effective mode for most biopharmaceuticals, while continuous (perfusion) offers advantages for unstable products or very high-demand molecules. Simple batch processes have the lowest operational complexity but also the lowest volumetric productivity, resulting in higher per-gram costs. Fed-batch typically achieves 3-10x higher titers than batch by extending the production phase with nutrient feeds, significantly reducing COGS. Continuous perfusion can achieve 5-10x the volumetric productivity of fed-batch on a per-liter-per-day basis, enabling smaller bioreactors for equivalent annual output. However, perfusion requires more complex equipment, longer campaign durations, and higher media consumption. The economic break-even depends on product titer, annual demand, and facility utilization.

Typical COGS for commercial-scale monoclonal antibody production ranges from $20-100 per gram of purified drug substance. At large scale (10,000-15,000 L bioreactors) with modern titers of 5-8 g/L, COGS can be as low as $20-50/g. At smaller clinical or early commercial scale (1,000-2,000 L), COGS is often $200-500/g due to underutilized facility capacity. Biosimilar manufacturers in Asia have reported COGS below $20/g at very large scale. These figures include all upstream and downstream processing, quality control, and facility costs, but typically exclude fill-finish, packaging, distribution, and regulatory costs. Single-use facilities generally have lower COGS at scales below 2,000 L, while stainless-steel facilities become more economical above that threshold.

Downstream processing costs are best estimated by summing consumable costs (resins, membranes, filters), buffer and water costs, labor, and equipment depreciation for each unit operation. For monoclonal antibodies, Protein A chromatography resin is often the single largest consumable cost at $8,000-15,000 per liter of resin, though modern resins tolerate 100-200 cycles. Calculate resin cost per gram of product based on binding capacity (typically 30-50 g/L resin), number of cycles, and resin lifetime. Add polishing chromatography steps (ion exchange, hydrophobic interaction), viral inactivation (low pH hold), viral filtration ($2,000-5,000 per filter), and ultrafiltration/diafiltration. Total downstream costs typically represent 50-80% of total COGS for low-titer processes but decrease proportionally as upstream titers improve.

Titer has the single largest impact on COGS, but the relationship is non-linear with diminishing returns above approximately 5 g/L. Doubling titer from 1 g/L to 2 g/L can reduce COGS by 30-40%, because fixed costs (facility, labor, utilities) are spread across more product. However, doubling from 5 g/L to 10 g/L may only reduce COGS by 10-15%, because downstream processing costs become the bottleneck and scale proportionally with product mass. At very high titers (>10 g/L), downstream processing can account for 70-80% of total COGS, making further titer improvements less impactful. The economic inflection point depends on your specific process, but most cost models show diminishing returns beyond 3-5 g/L for mAbs in standard fed-batch processes.